Trial Profile

VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nelipepimut-S (Primary) ; GM-CSF-transduced tumour cell vaccine; Sargramostim
Indications Carcinoma; Early breast cancer
Focus Pharmacodynamics
Acronyms VADIS

Most Recent Events

16 Nov 2023 Status changed from active, no longer recruiting to completed.
11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium
11 Dec 2020 According to a Sellas Life Sciences Group media release, final data with up to 6 months follow-up were presented at the 2020 San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com